Patents by Inventor Scott Caldwell

Scott Caldwell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions and methods for use
    Publication number: 20030087915
    Abstract: Pharmaceutical compositions incorporate aryl substituted olefinic amine compounds. Representative compounds are (2S)-(4E)-N-methyl-5-[3-(5-isopropoxy-1-oxopyridin)yl)]-4-penten-2-amine, (4E)-N-methyl-5-(3-(1-oxopyridin)yl)4-penten-2-amine, (4E)-N-methyl-5-(3-(5-((carboxymethyl)oxy)pyridin)yl)-4-penten-2-amine and (4E)-N-methyl-5-(3-(1-oxopyridin)yl)-4-penten-2-amine.
    Type: Application
    Filed: September 16, 2002
    Publication date: May 8, 2003
    Inventors: Gary Maurice Dull, Craig Harrison Miller, William Scott Caldwell, Dwo Lynm, Balwinder Singh Bhatti, Jeffrey Daniel Schmitt, Gary Dwight Byrd
  • Pyrimidinyl compounds for treatment of central nervous system disorders
    Patent number: 6555684
    Abstract: Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.
    Type: Grant
    Filed: October 9, 2001
    Date of Patent: April 29, 2003
    Assignee: Targacept, Inc.
    Inventors: William Scott Caldwell, Gary Maurice Dull, Grayland Page Dobson
  • Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds
    Patent number: 6531606
    Abstract: Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound. Exemplary compounds include (E)-N-methyl-4-[3-(5-benzyloxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-phenoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-isopropoxypyridin)yl]-3-buten-1-amine, (E)-N-methyl-4-[3-(5-methoxymethylpyridin)yl]-3-buten-1-amine, and (E)-N-methyl-4-[3-(5-phenylpyridin)yl]-3-buten-1-amine.
    Type: Grant
    Filed: February 21, 1997
    Date of Patent: March 11, 2003
    Assignee: Targacept, Inc.
    Inventors: Gary Maurice Dull, William Scott Caldwell, Grayland Page Dobson, Craig Harrison Miller
  • Pharmaceutical compositions and methods for effecting dopamine release
    Patent number: 6525065
    Abstract: Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) are treated by administering an endo or exo form of a 1-aza-2-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-2-(3-pyridyl)bicyclo[2.2.2]octane, a 1-aza-2-(3-pyridyl)bicyclo[3.2.2]nonane, a 1-aza-7-(3-pyridyl)bicyclo[2.2.1]heptane, a 1-aza-3-(3-pyridyl)bicyclo[3.2.2]nonane, or a 1-aza-7-(3-pyridyl)bicyclo[3.2.2]nonane.
    Type: Grant
    Filed: June 30, 1997
    Date of Patent: February 25, 2003
    Assignee: Targacept, Inc.
    Inventors: William Scott Caldwell, Merouane Bencherif, Gary Maurice Dull, Peter Anthony Crooks, Patrick Michael Lippiello
  • Pharmaceutical compositions and methods for use
    Patent number: 6492399
    Abstract: Pharmaceutical compositions incorporate aryl substituted olefinic amine compounds. Representative compounds are (3E)-N-methyl-4-[3-(5-nitro-6-aminopyridin)yl]-3-buten-1-amine, (3E)-N-methyl-4-[3-(5-(N-benzylcarboxamido)pyridin)yl]-3-buten-1-amine, (4E)-N-methyl-5-[5-(2-aminopyrimidin)yl]-4-penten-2-amine, (4E)-N-methyl-5-(3-(5-aminopyridin)yl)-4-penten-2-amine, (3E)-N-methyl-4-(3-(5-isobutoxypyridin)yl)-3-buten-1-amine, (3E)-N-methyl-4-(3-(1-oxopyridin)yl)-3-buten-1-amine, (3E)-N-methyl-4-(3-(5-ethylthiopyridin)yl)-3-buten-1-amine, (4E)-N-methyl-5-(3-(5-trifluoromethylpyridin)yl)-4-penten-2-amine and (4E)-N-methyl-5-(3-(5-hydroxypyridin)yl)-4-penten-2-amine.
    Type: Grant
    Filed: June 7, 1999
    Date of Patent: December 10, 2002
    Assignee: Targacept, Inc.
    Inventors: Gary Maurice Dull, Craig Harrison Miller, William Scott Caldwell, Srishailkumar Basawannappa Hadimani
  • Pharmaceutical compositions for inhibition of cytokine production and secretion
    Patent number: 6489349
    Abstract: Pharmaceutical compositions incorporate compounds that affect cytokine production and/or secretion. Such compounds include aryl substituted olefinic amine compounds, pyridyloxylalkylamines and phenoxyalkylamines, and aryl substituted amine compounds, such as 3-aminophenyl amine compounds. Such pharmaceutical compositions can be used for treating a wide variety of conditions, diseases and disorders, and particularly those associated with dysfunction of cytokine production and/or secretion. Of particular interest are pharmaceutical compositions useful for preventing and treating conditions, diseases and disorders associated with undesirably high levels of cytokine production and/or secretion. Such pharmaceutical compositions are useful for treating the effects of inflammatory bowel disease, inflammation, arthritis, cachexia in neoplastics diseases or associated with AIDS, and autoimmune diseases.
    Type: Grant
    Filed: September 6, 2000
    Date of Patent: December 3, 2002
    Assignee: Targacept, Inc.
    Inventors: Merouane Bencherif, William Scott Caldwell, Gary Maurice Dull, Grayland Page Dobson
  • Oxopyridinyl pharmaceutical compositions and methods for use
    Patent number: 6455554
    Abstract: Pharmaceutical compositions incorporate aryl substituted olefinic amine compounds. Representative compounds are (2S)-(4E)-N-methyl-5-[3-(5-isopropoxy-1-oxopyridin)yl)]-4-penten-2-amine, (4E)-N-methyl-5-(3-(1-oxopyridin)yl)-4-penten-2-amine, (4E)-N-methyl-5-(3-(5-((carboxymethyl)oxy)pyridin)yl)-4-penten-2-amine and (4E)-N-methyl-5-(3-(1-oxopyridin)yl)-4-penten-2-amine.
    Type: Grant
    Filed: May 12, 2000
    Date of Patent: September 24, 2002
    Assignee: Targacept, Inc.
    Inventors: Gary Maurice Dull, Craig Harrison Miller, William Scott Caldwell, Dwo Lynm, Balwinder Singh Bhatti, Jeffrey Daniel Schmitt, Gary Dwight Byrd
  • Pharmaceutical compositions and methods for use
    Patent number: 6417359
    Abstract: A compound having the formula: wherein X′ is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; X is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0, but not equal to 0; A, A′ and A″ are individually substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; Z′ is a substituent other than hydrogen; j is an integer from 0 to 5; and the wavy line in the structure indicates that the compound can exist in the form of an enantiomer or a diasteromer; Z″ is hydrogen or a substituent other than hydrogen; Y is C═O, C(OH)R′ or C—A, where R′ is hydrogen or lower alkyl.
    Type: Grant
    Filed: April 27, 2000
    Date of Patent: July 9, 2002
    Assignee: Targacept, Inc.
    Inventors: Peter Anthony Crooks, Haeil Park, Balwinder Singh Bhatti, William Scott Caldwell, Gary Maurice Dull
  • Compounds capable of activating cholinergic receptors
    Publication number: 20020052497
    Abstract: Compounds incorporating aryl substituted olefinic amine are provided. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.
    Type: Application
    Filed: October 9, 2001
    Publication date: May 2, 2002
    Applicant: Targacept, Inc.
    Inventors: William Scott Caldwell, Gary Maurice Dull, Balwinder Singh Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared Miller Wagner, Peter Anthony Crooks
  • Pharmaceutical compositions for prevention and treatment of central nervous system disorders
    Publication number: 20020032206
    Abstract: Patients susceptible to or suffering from central nervous system disorders are treated by administering effective amounts of aryl substituted aliphatic amine compounds, aryl substituted olefinic amine compounds or aryl substituted acetylenic amine compounds. A representative compound is (E)-N-methyl-5-(3-pyridinyl)-4-penten-2-amine.
    Type: Application
    Filed: October 9, 2001
    Publication date: March 14, 2002
    Inventors: William Scott Caldwell, Gary Maurice Dull, Garyland Page Dobson
  • Pharmaceutical compositions and methods for use
    Patent number: 6337351
    Abstract: Pharmaceutical compositions aryl substituted amine compounds, and in particular, 3-aminophenyl amine compounds are provided. Representative compounds are (4E)-N-methyl-5-(3-acetamido-4-methylphenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3-amino-4-methylphenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3-(dimethylamino)phenyl)-4-penten-2-amine, (4E)-N-methyl-5-(4-methyl-3-nitrophenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3-fluorophenyl)-4-penten-2-amine, (4E)-N-methyl-5-(3,4-dichlorophenyl)-4-penten-2-amine and (4E)-N-methyl-5-(3,4-methylenedioxyphenyl)-4-penten-2-amine.
    Type: Grant
    Filed: September 8, 1999
    Date of Patent: January 8, 2002
    Assignee: Targacept, Inc.
    Inventors: Gary Maurice Dull, Jared Miller Wagner, William Scott Caldwell, Craig Harrison Miller, Jeffrey Daniel Schmitt, Balwinder Singh Bhatti, Srishailkumar Basawannappa Hadimani
  • Pharmaceutical compositions and methods for use
    Patent number: 6310102
    Abstract: Pharmaceutical compositions aryl substituted amine compounds, and in particular, 3-aminophenyl amine compounds are provided. Representative compounds are (E)-4-(3-aminophenyl)-3-buten-1-amine, (E)-N-methyl-4-(3-aminophenyl)-3-buten-1-amine and (E)-N-methyl-5-(3-aminophenyl)-4-penten-2-amine.
    Type: Grant
    Filed: March 7, 2000
    Date of Patent: October 30, 2001
    Assignee: Targacept, Inc.
    Inventors: Gary Maurice Dull, Jared Miller Wagner, William Scott Caldwell, Craig Harrison Miller, Jeffrey Daniel Schmitt, Balwinder Singh Bhatti, Srishailkumar Basawannappa Hadimani
  • Methods of treating central nervous system disorders with aryl substituted olefinic amine compounds
    Patent number: 6274606
    Abstract: Patients susceptible to or suffering from central nervous system disorders (e.g., Alzheimer's disease, Parkinson's disease, Tourette's syndrome, attention deficit disorder or schizophrenia) are treated by administering an effective amount of an aryl substituted olefinic amine compound. Exemplary compounds include, (E)-N-methyl-4-[3-(5-isopropoxypyridin)yl]-3-buten-1-amine, and (E)-N-methyl-4-[3-(5-methoxymethylpyridin)yl]-3-buten-1-amine.
    Type: Grant
    Filed: October 12, 1998
    Date of Patent: August 14, 2001
    Assignee: Targacept, Inc.
    Inventors: William Scott Caldwell, Gary Maurice Dull, Merouane Bencherif, Patrick Michael Lippiello
  • Pharmaceutical compositions and methods for use
    Patent number: 6262124
    Abstract: Pharmaceutical compositions aryl substituted amine compounds, and in particular, 3-aminophenyl amine compounds are provided. Representative compounds are (E)-4-(3-aminophenyl)-3-buten-1-amine, (E)-N-methyl-4-(3-aminophenyl)-3-buten-1-amine and (E)-N-methyl-5-(3-aminophenyl)-4-penten-2-amine.
    Type: Grant
    Filed: October 22, 1998
    Date of Patent: July 17, 2001
    Inventors: Gary Maurice Dull, Jared Miller Wagner, William Scott Caldwell, Craig Harrison Miller, Jeffrey Daniel Schmitt, Balwinder Singh Bhatti, Srishailkumar Basawannappa Hadimani
  • Methods for treatment of CNS disorders
    Patent number: 6232316
    Abstract: Pharmaceutical compositions incorporate aryl substituted olefinic amine compounds. Representative compounds are (4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-pyrimidinyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-methoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(6-amino-5-methyl-3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (2R)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-bromo-3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-ethoxy-3-pyridyl)-4-penten-2-amine, (2S)-(4E)-N-methyl-5-(3-pyridyl)-4-penten-2-amine, (4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine and (2S)-(4E)-N-methyl-5-(5-isopropoxy-3-pyridyl)-4-penten-2-amine.
    Type: Grant
    Filed: June 16, 1998
    Date of Patent: May 15, 2001
    Assignee: Targacept, Inc.
    Inventors: Gary Maurice Dull, William Scott Caldwell, Patrick Michael Lippiello, Merouane Bencherif
  • Methods for prevention and treatment of Tourette's syndrome and schizophrenia
    Patent number: 6107298
    Abstract: Patients susceptible to or suffering from Tourette's syndrome or schizophrenia are treated by administering an effective amount of an aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyly-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyrindin)yl]-3-butene-1-amine, (Z)-metanicotine, (E)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4-[3-(6-methylpyrindin)yl]-3-butene-1-amine.
    Type: Grant
    Filed: March 12, 1999
    Date of Patent: August 22, 2000
    Inventors: Merouane Bencherif, Patrick Michael Lippiello, William Scott Caldwell, Gary Maurice Dull
  • Pharmaceutical compositions for prevention and treatment of central nervous system disorders
    Patent number: 6100269
    Abstract: Patients susceptible to or suffering from central nervous system disorders (e.g., neurodegenerative diseases including presenile dementia, senile dementia of the Alzheimer's type, and Parkinsonism including Parkinson's disease, and other CNS disorders including attention deficit disorder, schizophrenia and Tourette's syndrome) are treated by administering an effective amount of 2-azabicyclo [2.2.1] heptane and 2-azabicyclo [2.2.2] octane compounds.
    Type: Grant
    Filed: May 6, 1999
    Date of Patent: August 8, 2000
    Inventors: Merouane Bencherif, William Scott Caldwell, Gary Maurice Dull, Patrick Michael Lippiello
  • Certain 1-aza-tricyclo [3.3.1-1.sup.3,7 ] decane compounds
    Patent number: 6057446
    Abstract: A compound having the formula: ##STR1## wherein X' is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; X is nitrogen or carbon bonded to a substituent species characterized as having a sigma m value greater than 0, less than 0, but not equal to 0; A, A' and A" are individually substituent species characterized as having a sigma m value greater than 0, less than 0 or 0; Z' is a substituent other than hydrogen; j is an integer from 0 to 5; and the wavy line in the structure indicates that the compound can exist in the form of an enantiomer or a diasteromer; Z" is hydrogen or a substituent other than hydrogen; Y is C.dbd.O, C(OH)R' or C--A, where R' is hydrogen or lower alkyl.
    Type: Grant
    Filed: April 2, 1998
    Date of Patent: May 2, 2000
    Inventors: Peter Anthony Crooks, Haeil Park, Balwinder Singh Bhatti, William Scott Caldwell, Gary Maurice Dull
  • Pharmaceutical compositions for prevention and treatment of central nervous system disorders
    Patent number: 5922723
    Abstract: Patients susceptible to or suffering from central nervous system disorders (e.g., neurodegenerative diseases including presenile dementia, senile dementia of the Alzheimer's type, and Parkinsonism including Parkinson's disease, and other CNS disorders including attention deficit disorder, schizophrenia and Tourette's syndrome) are treated by administering an effective amount of 2-azabicyclo ?2.2.1! hept-5-ene and 2-azabicyclo ?2.2.2! oct-5-ene compounds.
    Type: Grant
    Filed: September 5, 1996
    Date of Patent: July 13, 1999
    Inventors: Merouane Bencherif, William Scott Caldwell, Gary Maurice Dull, Patrick Michael Lippiello
  • Methods for prevention and treatment of attention deficit disorder
    Patent number: 5885998
    Abstract: Patients susceptible to or suffering from attention deficit disorder are treated by administering an effective amount of an aryl subsistituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-?3-(5-methoxypyridin)yl!-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-?3-(5-methoxypyrindin)yl!-3-butene-1-amine, (Z)-metanicotine, (E)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4-?3-(6-methylpyrindin)yl!-3-butene-1-amine.
    Type: Grant
    Filed: February 12, 1998
    Date of Patent: March 23, 1999
    Inventors: Merouane Bencherif, Patrick Michael Lippiello, William Scott Caldwell, Gary Maurice Dull